FAPI PET新视角:在心血管疾病中的应用进展  

New perspectives on FAPI PET:advances in cardiovascular disease

作　　者：尹凤 赵军[1] Yin Feng;Zhao Jun(Department of Nuclear Medicine,Shanghai East Hospital,School of Medicine,Tongji University,Shanghai 200120,China)

机构地区：[1]同济大学附属东方医院核医学科,上海200120

出　　处：《中华核医学与分子影像杂志》2024年第11期693-696,共4页Chinese Journal of Nuclear Medicine and Molecular Imaging

基　　金：上海市浦东新区卫生系统重点学科建设项目(PWZxk2022-12)。

摘　　要：成纤维细胞激活蛋白(FAP)是1种膜锚定的肽酶。自2019年研发以来,FAP抑制剂(FAPI)PET显像已广泛应用于恶性肿瘤的诊断、分期、疗效评估及预后。在恶性肿瘤的应用中,偶然发现FAPI在心血管系统中有摄取,这引发了有关FAPI显像对心血管疾病的诊断和预后价值的思考。该文对此进行总结。Fibroblast activating protein(FAP)is a membrane-anchored peptidase.Since its development in 2019,PET imaging of FAP inhibitor(FAPI)has been widely used in the diagnosis,staging,efficacy evaluation and prognosis of malignant tumors.The accidental discovery of FAPI uptake in the cardiovascular system in the application of malignant tumors has led to the consideration of the diagnostic and prognostic value of FAPI imaging in cardiovascular diseases.This article makes a relevant summary.

关 键 词：心血管疾病 拮抗剂和抑制剂 膜蛋白质类 成纤维细胞 正电子发射断层显像术 发展趋势 

分 类 号：R54[医药卫生—心血管疾病] R817.4[医药卫生—内科学]